Skip to main
TRML
TRML logo

TRML Stock Forecast & Price Target

TRML Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tourmaline Bio Inc has experienced over a 30% increase in its stock price, with an estimated market value of $1.29 billion, translating to approximately $50 per share. The anticipated TRANQUILITY data is likely to generate increasing market interest, particularly in light of competitive study outcomes, such as the CANTOS study, which demonstrated a significant reduction in cardiovascular risks associated with anti-IL-6 treatments. Furthermore, forecasts suggest that potential ex-US revenues could reach $1 billion, with a mid-20% royalty assignment, which could enhance the company's valuation to around $53 per share, positioning it favorably within the biotechnology sector.

Bears say

Tourmaline Bio Inc has experienced a significant decline in stock performance, with shares down 35% year-to-date compared to a 1% gain in the NASDAQ Biotechnology Index. The company's financial outlook is further challenged by a potential decrease in fair value estimates: completely removing pipeline credit could lead to a valuation drop to approximately $10 per share, while a delay in clinical developments might reduce fair value to $32 per share. Additionally, significant risks are associated with the pacibekitug program due to possible failures in advancing ASCVD efforts or unfavorable competitor data, which could adversely impact the company's growth potential and investor confidence.

TRML has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tourmaline Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tourmaline Bio Inc (TRML) Forecast

Analysts have given TRML a Buy based on their latest research and market trends.

According to 10 analysts, TRML has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $55.70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $55.70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tourmaline Bio Inc (TRML)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.